Sulfur

Summary

Sulfur (CHEMBL1235452) is an approved small molecule (ATC D10AB02); indicated across 2 conditions including acne.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D10AB02 (+1 more)
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 256.5 Da · S8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1235452
Name	Sulfur
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	66348
ChEBI	CHEBI:29385
ATC	D10AB02, D11AC08
Molecular formula	S8
Molecular weight	256.5
InChIKey	JLQNHALFVCURHW-UHFFFAOYSA-N

SMILES: S1SSSSSSS1

IUPAC name: octathiocane

ChEBI definition: A homomonocyclic compound composed of eight sulfur atoms. It has been isolated from Ganoderma lucidum, a mushroom commonly used in Chinese medicine.

Other ChEBI roles (chemical / environmental): fungal metabolite, bacterial metabolite.

Also known as: .alpha.-sulfur, Acnaveen, Acnil, Bensulfoid, Colloidal sulfur, Colloidal sulphur, Cuticura, Dome-acne, Eskamel, Liu huang, Meted, NSC-403664

Patent coverage: 947,705 distinct patent families (2,163,993 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Carbonic anhydrase 2, Carbonic anhydrase 1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CA1	6.22	Ki	600	nM	CHEMBL_ACT_5131740

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acne	4	MONDO:0011438	EFO:0003894

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE4	2
PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01260571	PHASE4	UNKNOWN	Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples)
NCT02287675	PHASE4	COMPLETED	Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer
NCT06396507	PHASE3	COMPLETED	Sulfur vs. Different Regimes of Permethrin for Scabies
NCT05862701	PHASE1	COMPLETED	Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies
NCT02065232	Not specified	COMPLETED	Sentinel Lymph Node Mapping Post-Injection Site Pain

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).